Find Funding Opportunities

Notice Extend Expiration Date PAR-18-710 Career Transition Award NINDS Intramural Clinician-Scientists K22 Clinical Trial Required)" Notice Number: NOT-NS-19-065 Key Dates Release Date: 7, 2019 Related Announcements PAR-18-710 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants the expiration Date PAR-18-710 Career Transition Award NINDS Intramural Clinician-Scientists K22 Clinical Trial Required)" be extended one Council round changes shown bold italics below).  Funding Opportunity Announcement been modified add additional New Application Due date of June 12, 2019 and resubmission application due date of July 12, 2019. Currently Reads: Part 1. Overview Key Dates: Application Due Date(s) Standard dates , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date 8, 2019 Modified Read: Part 1. Overview Key Dates: Application Due Date(s) Standard dates , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date July 13, 2019 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-4188 Email: korns@ninds.nih.gov

Notice Clarification RFA-NS-18-043, Discovery Validation Novel Targets Safe Effective Pain Treatment R01 Clinical Trial Allowed)" Notice Number: NOT-AT-19-024 Key Dates Release Date: 7, 2019 Related Announcements RFA-NS-18-043 Issued National Center Complementary Integrative Health NCCIH) Purpose purpose this Notice to clarify Research Objectives” section for RFA-NS-18-043, Discovery Validation Novel Targets Safe Effective Pain Treatment R01 Clinical Trial Allowed)”. below revisions effective immediately apply the July 11, 2019 Application Due Date. Part 2. Full Text Announcement Section I. Funding Opportunity Description Research Objectives Currently reads: Applications identify targets devices, such peripheral nerve, spinal cord, deep brain stimulators focus identifying electrophysiological signatures acute chronic pain. Validation these targets large animals nonhuman primates should considered. Revised read: Applications identify validate targets devices such invasive non-invasive nerve stimulators, or acupoint-based other transcutaneous peripheral stimulations acute chronic pain. Applications identify either nervous system targets non-neural targets e.g., connective tissues, lymphatic, glymphatic targets) pain. Validation these targets large animals nonhuman primates should considered. Applications propose discovery validation targets any sensory systems e.g., olfaction, vision, audition, somatosensation, interoception, etc.) acute chronic pain. includes targets pharmacological well non-pharmacological approaches e.g., mind-body approaches, natural products, devices). Studies focused the efficacy effectiveness a therapeutic molecule a type treatment, such yoga acupuncture, pain not responsive this RFA, even this only part the application. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Inna Belfer, MD, PhD National Center Complementary Integrative Health NCCIH) Telephone: 301-435-1573 Email: inna.belfer@nih.gov Michael L. Oshinsky, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9964 Email: michael.oshinsky@nih.gov

Notice Clarification RFA-NS-18-042, Discovery Validation Novel Targets Safe Effective Pain Treatment R21 Clinical Trial Allowed)" Notice Number: NOT-AT-19-026 Key Dates Release Date: 7, 2019 Related Announcements RFA-NS-18-042 Issued National Center Complementary Integrative Health NCCIH) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to clarify Research Objectives” section for RFA-NS-18-042, Discovery Validation Novel Targets Safe Effective Pain Treatment R21 Clinical Trial Allowed)”. below revisions effective immediately apply the July 11, 2019 Application Due Date. Part 2. Full Text Announcement Section I. Funding Opportunity Description Research Objectives Currently reads: Applications identify targets devices, such peripheral nerve, spinal cord, deep brain stimulators focus identifying electrophysiological signatures acute chronic pain. Validation these targets large animals nonhuman primates should considered. Revised read: Applications identify validate targets devices such invasive non-invasive nerve stimulators, or acupoint-based other transcutaneous peripheral stimulations acute chronic pain. Applications identify either nervous system targets non-neural targets e.g., connective tissues, lymphatic, glymphatic targets) pain. Validation these targets large animals nonhuman primates should considered. Applications propose discovery validation targets any sensory systems e.g., olfaction, vision, audition, somatosensation, interoception, etc.) acute chronic pain. includes targets pharmacological well non-pharmacological approaches e.g., mind-body approaches, natural products, devices). Studies focused the efficacy effectiveness a therapeutic molecule a type treatment, such yoga acupuncture, pain not responsive this RFA, even this only part the application. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Inna Belfer, MD, PhD National Center Complementary Integrative Health NCCIH) Telephone: 301-435-1573 Email: inna.belfer@nih.gov Michael L. Oshinsky, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9964 Email: michael.oshinsky@nih.gov

Request Information: Research Plan Rehabilitation Notice Number: NOT-HD-19-006 Key Dates Release Date: April 23, 2019 Response Date: June 17, 2019 Related Announcements NOT-HD-15-032 Issued Eunice Kennedy ShriverNational Institute Child Health Human Development NICHD) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) National Institute Deafness Other Communication Disorders NIDCD) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Purpose TheEunice Kennedy ShriverNational Institute Child Health Human Development NICHD), National Center Medical Rehabilitation Research inviting comments suggestions guide revision the Research Plan Rehabilitation behalf the Trans NIH Medical Rehabilitation Coordinating Committee. Background 2016, National Institutes Health published Research Plan Rehabilitation outlined priorities the Institutes Centers advance rehabilitation science https://www.nichd.nih.gov/sites/default/files/publications/pubs/Documen…). Since time, NIH promoted multiple initiatives, workshops, funding opportunities aimed advancing priorities within research plan. Moreover, National Center Medical Rehabilitation Research theEunice Kennedy ShriverNational Institute Child Health Human Development presented annual updates the changes the portfolio following publication the research plan the National Advisory Board Medical Rehabilitation Research https://www.nichd.nih.gov/about/advisory/nabmrr). Information Requested NIH Medical Rehabilitation Coordinating Committee beginning update the research plan, required the 21stCentury Cures Act 42 USC 285g-4), is seeking guidance the community stakeholders involved this research. Specifically, NIH requests feedback the following: communitys perception progress towards achieving priorities specified the research plan, Potential priorities areas research consider the update the research plan, Current priorities should retained continued, Emerging areas science will impact research plan rehabilitation, Potential focus areas concentrated work medical rehabilitation research. feedback garnered this request information be reported the 2019 meeting the National Advisory Board Medical Rehabilitation Research will incorporated the update the Research Plan Rehabilitation is planned 2021. to Submit Response comments must submitted electronically Rehabilitation1@mail.nih.gov. Responses longer 300 words Microsoft or PDF format) must received 11:59:59 ET) the response date noted above.Please indicate RFI Reponse" the subject line the email.You receive electronic confirmation acknowledging receipt your response. Responses this RFI voluntary. not include any proprietary, classified, confidential, trade secret, sensitive information your response. responses be reviewed NIH staff, individual feedback not provided any responder. U.S. Government use information submitted response this RFI its discretion. U.S. Government reserves right use any submitted information public NIH websites, reports, summaries the state the science, any possible resultant solicitation(s), grant(s), cooperative agreement(s), in development future funding opportunity announcements. RFI for information planning purposes only shall be construed a solicitation, grant, cooperative agreement, as obligation the part the Federal Government, NIH, individual NIH Institutes Centers provide support any ideas identified response it. Government not pay the preparation any information submitted for U.S. Governments of such information. basis claims against U.S. Government shall arise a result a response this request information from Governments of such information. Inquiries Please direct inquiries to: Alison N. Cernich, PhD Eunice Kennedy ShriverNational Institute Child Health Human Development NICHD) Telephone: 301-496-0295 Email: Rehabilitation@nih.gov

Notice Change Key Dates RFA-NS-18-014 BRAIN Initiative: Targeted BRAIN Circuits Planning Projects - TargetedBCPP R34 Clinical Trial Allowed)" Notice Number: NOT-NS-19-034 Key Dates Release Date: April 18, 2019 Related Announcements RFA-NS-18-014 Issued National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) Office Behavioral Social Sciences Research OBSSR) Office Research Women’s Health ORWH) Purpose purpose this Notice to inform applicants a change the Key Dates RFA-NS-18-014 Targeted BRAIN Circuits Planning Projects - TargetedBCPP R34 Clinical Trial Allowed)". Three new receipt dates been added the FOA: November 6, 2019, July 1, 2020,and November 10, 2020. Additionally, Peer Review Contact changed Alexei Kondratyev, Ph.D. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) March 15, 2018; July 17, 2018; July 15, 2019 Scientific Merit Review June 2018; October 2018; October 2019 Advisory Council Review August 2018; January 2019; January 2020 Earliest Start Date September 2018; April 2019; April 2020 Expiration Date July 16, 2019 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) March 15, 2018; July 17, 2018; July 15, 2019; November 6, 2019; July 1, 2020; November 10, 2020 Scientific Merit Review June 2018; October 2018; October 2019; February 2020; October 2020; February 2021 Advisory Council Review August 2018; January 2019; January 2020; May 2020; January 2021; 2021 Earliest Start Date September 2018; April 2019; April 2020; June 2020; February 2021; June 2021 Expiration Date November 10, 2021 Currently Reads: Section II. Award Information Funds Available Anticipated Number Awards BRAIN Initiative partner componentsintend commit estimated total 2.5M fund 10 awards. Modified Read: Section II. Award Information Funds Available Anticipated Number Awards BRAIN Initiative partner componentsintend commit estimated total 2.5M fund 10 awards for FY21.   Currently Reads: Section VII. Agency Contact(s) Scientific/Research Contact(s) James Gnadt, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9964 Email:BRAINCircuits@NIH.GOV Peer Review Contact(s) Nick Gaiano, PhD Center Scientific Review CSR) Telephone: 301-435-1033 Email:nick.gaiano@nih.gov Modified Read: Section VII. Agency Contact(s) Scientific/Research Contact(s) Karen K David, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9964 Email:BRAINCircuits@NIH.GOV Peer Review Contact(s) Alexei Kondratyev, Ph.D. Center Scientific Review CSR) Telephone: 301-465-1785 Email: alexei.kondratyev@nih.gov other aspects this FOA remain same. Inquiries Please direct inquiries to: Karen K David, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9964 Email: BRAINCircuits@nih.gov

Notice Intent Publish Reissuance RFA-NS-19-025" HEAL Initiative: Early Phase Pain Investigation Clinical Network - Specialized Clinical Centers U24 Clinical Trial Allowed)" Notice Number: NOT-NS-19-051 Key Dates Release Date:April 11, 2019 Estimated Publication Date Funding Opportunity Announcement: April 22, 2019 First Estimated Application Due Date: June 03, 2019 Earliest Estimated Award Date: November 01, 2019 Earliest Estimated Start Date: December 01, 2019 Related Announcements RFA-NS-19-025 Issued National Institutes Health NIH) National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke intends re-issue Funding Opportunity Announcement FOA) solicit additional applications regional clinical centers associated clinical research sites the Early Phase Pain Investigation Clinical Network EPPIC-Net). EPPIC-Net be charged executing early phase trials high impact the treatment patients acute chronic pain. regional clinical centers ("hubs" their linked clinical research sites ("spokes") conduct clinical trials concert a network Clinical Coordinating Center CCC) a Data Coordinating Center DCC). Approximately ten regional clinical center Hubs anticipated be funded. purpose this notice to allow potential Hub applicants sufficient time develop meaningful plans collaborations their linked clinical center spokes support their application. EPPIC-Net part the NIH Helping End Addiction Long-Term HEAL) Initiative. EPPIC-Net enable exploratory clinical trials investigational drugs biologics, investigational devices, natural products, surgical procedures the treatment specific types pain. Thesetrials validate biomarkers, provide proof concept, otherwise contribute the justification proceeding not proceeding a futurePhase 3 trial e.g., informing go/no-go decisions). Interventions trials within EPPIC-Net be solicited the national international scientific community. Interventions e.g. investigational drugs, devices biologics) studied within EPPIC-Net be provided companies academic institutions. populations be studied include those well-defined pain conditions with high unmet needs, example chronic neuropathic, inflammatory nociceptive pain disorders adult pediatric populations. EPPIC-Net focus Phase 2 trials is anticipated be able run many five Phase 2 trials concurrently, addition biomarker validation studies. EPPIC-Net infrastructure also include repository HEAL initiative data samples facilitate future research discovery. TheEPPIC-Net Hubs work the EPPIC-Net CCC, DCC other hubs selected particular studies. Hub envisioned a regional medical center is center excellence encompassing medical expertise neurology, anesthesiology, rheumatology, obstetrics/gynecology, pediatrics, orthopedics, physical medicine, gastroenterology, and/or subspecialties providing care patients pain. Hub willenroll patients along its network 2-10 research spokes will additionally provide scientific leadership administrative oversight its multiple spokes. notice informs clinical centers excellence the forthcoming solicitation applications EPPIC-Net hubs. Research Initiative Details Hub must a flexible network Spokes. principal function the Spokes to provide access a sufficiently large patient population support trial enrollment. Spokes should selected increase access patients a particular pain disease pain syndrome, encompass patients underserved communities, and/or complement Hub providing access specific research clinical expertise. each clinical trial, Hub be expected assemble network 2-10 Spokes specifically tailored the needs that particular trial. Since requirements each clinical trial vary, identity configuration Spokes be unique each trial. Therefore, Hub should relationships a number potential Spokes the ability add Spokes appropriate the study. demonstrate ability attract Spokes, applicant requested identify, the time application, five Spokes committed participation at least clinical trial.Since five initial Spokes unlikely be able meet possible future clinical trial requirements, Hub need incorporate plan mechanism recruiting additional Spokes needed. Funding Information Estimated Total Funding TBD Expected Number Awards TBD Estimated Award Ceiling TBD Primary CFDA Numbers 93.853 Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Nonprofit without 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) Indian/Native American Tribal Government than Federally Recognized) Regional Organization Applications not being solicited this time.  Inquiries Please direct inquiries to: Barbara I. Karp, M.D.National Institute Neurological Disorders Stroke NINDS)301-496-0150karpb@ninds.nih.gov

Notice Correction Application Types Allowed RFA-NS-19-017 HEAL Initiative: Translational Devices Treat Pain U44 Clinical Trial Optional)" Notice Number: NOT-NS-19-052 Key Dates Release Date: April 10, 2019 Related Announcements RFA-NS-19-017 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform potential applicants a correction Application Types Allowed in response to RFA-NS-19-017 "HEAL Initiative: Translational Devices Treat Pain U44 Clinical Trial Optional)". Renewal Direct Phase II applications allowed this Funding Opportunity Announcement.  notice be effective the June 21, 2019 application due date subsequent due dates. following section of RFA-NS-19-017 has modified shown bold-italics below): Currently Reads: Section II. Award Information Funding Instrument: Cooperative Agreement: support mechanism used there be substantial Federal scientific programmatic involvement. Substantial involvement means that, after award, NIH scientific program staff assist, guide, coordinate, participate project activities. Section VI.2 additional information the substantial involvement this FOA. Application Types Allowed: Revision New Fast-Track) New Phase II* SBIR Direct Phase II Only) Renewal(Phase II* Direct Phase II allowed) Resubmission phases) The OER Glossary and SF424 R&R) Application Guide provide details these application types. Modified Read: Section II. Award Information Funding Instrument: Cooperative Agreement: support mechanism used there be substantial Federal scientific programmatic involvement. Substantial involvement means that, after award, NIH scientific program staff assist, guide, coordinate, participate project activities. Section VI.2 additional information the substantial involvement this FOA. Application Types Allowed: Revision New Fast-Track) New Phase II* SBIR Direct Phase II Only) Renewal (Phase II) Resubmission phases) The OER Glossary and SF424 R&R) Application Guide provide details these application types. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Nick Langhals, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email:nick.langhals@nih.gov

Notice Change Key Dates RFA-NS-19-016 HEAL Initiative: Translational Devices Treat Pain UG3/UH3 Clinical Trial Optional)" Notice Number: NOT-NS-19-053 Key Dates Release Date: April 10, 2019 Related Announcements RFA-NS-19-016 Issued National Institute Neurological Disorders Stroke NINDS) National Cancer Institute NCI) National Eye Institute NEI) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Nursing Research NINR) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) Office Research Women’s Health ORWH) Purpose purpose this notice to change Key Dates in RFA-NS-19-016 "HEAL Initiative: Translational Devices Treat Pain UG3/UH3 Clinical Trial Optional)". Specifically, additional receipt been added the August Council round May 20, 2019 changes in bold italics below). Although letter intent not required, not binding, does enter the review a subsequent application, applicants strongly encouraged submit letter intent this receipt date, allow IC staff estimate potential review workload plan review. Part 1. Overview Key Dates Currently Reads: Application Due Date(s) January 9, 2019, March 22, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 21, 2021 , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review April 2019, June 2019, November 2019, March 2020, June 2020, November 2020, March 2021, June 2021 Advisory Council Review 2019, August 2019, January 2020, 2020, August 2020, January 2021, 2021, August 2021 Earliest Start Date July 2019, October 2019, March 2020, July 2020, October 2020, March 2021,July 2021, October 2021 Modified Read: Application Due Date(s) January 9, 2019, March 22, 2019, May 20, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 21, 2021 , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review April 2019, June 2019, June 2019, November 2019, March 2020, June 2020, November 2020, March 2021, June 2021 Advisory Council Review 2019, August 2019, August 2019, January 2020, 2020, August 2020, January 2021, 2021, August 2021 Earliest Start Date July 2019, October 2019, October 2019, March 2020, July 2020, October 2020, March 2021,July 2021, October 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Nick Langhals, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email:nick.langhals@nih.gov

Notice Change Key Dates RFA-NS-19-017 HEAL Initiative: Translational Devices Treat Pain U44 Clinical Trial Optional)" Notice Number: NOT-NS-19-054 Key Dates Release Date: April 10, 2019 Related Announcements RFA-NS-19-017 Issued National Institute Neurological Disorders Stroke NINDS) National Cancer Institute NCI) National Eye Institute NEI) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Nursing Research NINR) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) Office Research Women’s Health ORWH) Purpose purpose this notice to change Key Dates in RFA-NS-19-017 "HEAL Initiative: Translational Devices Treat Pain U44 Clinical Trial Optional)". Specifically, additional receipt been added the August Council round May 20, 2019 changes in bold italics below). Although letter intent not required, not binding, does enter the review a subsequent application, applicants strongly encouraged submit letter intent this receipt date, allow IC staff estimate potential review workload plan review. Part 1. Overview Key Dates Currently Reads: Application Due Date(s) January 9, 2019, March 22, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 21, 2021 , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review April 2019, June 2019, November 2019, March 2020, June 2020, November 2020, March 2021, June 2021 Advisory Council Review 2019, August 2019, January 2020, 2020, August 2020, January 2021, 2021, August 2021 Earliest Start Date July 2019, October 2019, March 2020, July 2020, October 2020, March 2021,July 2021, October 2021 Modified Read: Application Due Date(s) January 9, 2019, March 22, 2019, May 2 0, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 21, 2021 , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review April 2019, June 2019, June 2019, November 2019, March 2020, June 2020, November 2020, March 2021, June 2021 Advisory Council Review 2019, August 2019, August 2019, January 2020, 2020, August 2020, January 2021, 2021, August 2021 Earliest Start Date July 2019, October 2019, October 2019, March 2020, July 2020, October 2020, March 2021,July 2021, October 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Nick Langhals, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email:nick.langhals@nih.gov

Notice Change Key Dates RFA-NS-19-018 HEAL Initiative: Clinical Devices Treat Pain UH3 Clinical Trial Optional)" Notice Number: NOT-NS-19-055 Key Dates Release Date: April 10, 2019 Related Announcements RFA-NS-19-018 Issued National Institute Neurological Disorders Stroke NINDS) National Cancer Institute NCI) National Eye Institute NEI) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Nursing Research NINR) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) Office Research Women’s Health ORWH) Purpose purpose this notice to change Key Dates in RFA-NS-19-018 "HEAL Initiative: Clinical Devices Treat Pain UH3 Clinical Trial Optional)". Specifically, additional receipt been added the August Council round May 20, 2019 changes in bold italics below). Although letter intent not required, not binding, does enter the review a subsequent application, applicants strongly encouraged submit letter intent this receipt date, allow IC staff estimate potential review workload plan review. Part 1. Overview Key Dates Currently Reads: Application Due Date(s) January 9, 2019, March 22, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 21, 2021 , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review April 2019, June 2019, November 2019, March 2020, June 2020, November 2020, March 2021, June 2021 Advisory Council Review 2019, August 2019, January 2020, 2020, August 2020, January 2021, 2021, August 2021 Earliest Start Date July 2019, October 2019, March 2020, July 2020, October 2020, March 2021,July 2021, October 2021 Modified Read:  Application Due Date(s) January 9, 2019, March 22, 2019, May 20, 2019 , June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 21, 2021 , 5:00 PM local time applicant organization. All types non-AIDS applicationsallowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date.   Scientific Merit Review April 2019, June 2019, June 2019, November 2019, March 2020, June 2020, November 2020, March 2021, June 2021 Advisory Council Review 2019, August 2019, August 2019, January 2020, 2020, August 2020, January 2021, 2021, August 2021 Earliest Start Date July 2019, October 2019, October 2019, March 2020, July 2020, October 2020, March 2021,July 2021, October 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Nick Langhals, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email:nick.langhals@nih.gov